Cart
Research Literature Overview

BPC-157 & TB-500: Tissue Repair Research in Current Literature

Published August 2, 2026 · Updated September 30, 2026 · ROVIQ Research

Key points
What are BPC-157 and TB-500?
BPC-157 is a synthetic pentadecapeptide, and TB-500 is a synthetic peptide based on the active region of thymosin beta-4. Both are studied in tissue-repair research.
What kind of evidence exists for BPC-157 and TB-500?
The published evidence for both is almost entirely preclinical, rodent studies and in vitro work, with no completed human clinical trials in the peer-reviewed literature.
What have the animal studies measured?
In rat models, BPC-157 studies measured new blood-vessel formation in granulation tissue and the repair of a muscle-tendon junction defect, and thymosin beta-4 studies measured wound re-epithelialization and collagen deposition. A 2019 review notes that most BPC-157 studies used small rodent models and that its efficacy "is yet to be confirmed in humans".

BPC-157 (a synthetic pentadecapeptide) and TB-500 (a synthetic peptide based on the active region of thymosin beta-4) are two of the most frequently studied compounds in tissue-repair research. Unlike some other compound classes, the published evidence base for both is almost entirely preclinical — rodent studies and in vitro work — with no completed human clinical trials in the peer-reviewed literature. This overview summarizes what that animal-model and cell-based research actually shows.

BPC-157: Angiogenesis and Granulation Tissue

One of the earliest published findings on BPC-157 was its angiogenic (blood-vessel-forming) effect. Using a subcutaneous sponge implantation model in rats, researchers found that BPC-157 markedly increased the formation of new endothelial spaces within granulation tissue, describing an "evident angiogenic property" comparable in magnitude to sucralfate, an established agent studied for similar effects (Sikiric et al., 1999).

BPC-157: Muscle-Tendon Junction Repair

A 2021 study examined a myotendinous junction defect in rats — a type of injury that does not heal spontaneously in the animal model used. Rats treated with BPC-157 showed counteracted muscle atrophy and functional recovery, assessed via biomechanical testing and molecular markers, compared to persistent defects and progressive muscle wasting in untreated controls (Japjec et al., 2021).

What the broader literature says: a 2019 review in Cell and Tissue Research summarizing BPC-157 soft-tissue-healing studies notes that results have been consistently positive across various injury models — but is explicit that "the majority of studies have been performed on small rodent models and the efficacy of BPC 157 is yet to be confirmed in humans" (Gwyer et al., 2019).

Thymosin Beta-4 / TB-500: Wound Healing and Re-epithelialization

TB-500 is a synthetic peptide derived from the active fragment of thymosin beta-4 (Tβ4), the naturally occurring protein most peptide research on this pathway is actually published under. A foundational 1999 study found that thymosin beta-4 increased wound re-epithelialization by 42% at day 4 and 61% at day 7 in a rat model, compared to saline controls, along with increased collagen deposition and accelerated keratinocyte migration in cultured cells (Malinda et al., 1999).

A follow-up study in rodent models found thymosin beta-4 promoted angiogenesis and wound repair in both young and aged animals, with an additional, separately noted effect on hair follicle development (Philp et al., 2004).

Important distinction: every study cited above is preclinical — conducted in rats, mice, or cultured cells, using controlled laboratory dosing and delivery methods specific to each experiment. None of these studies were conducted in humans, and none evaluated the specific research compounds sold by ROVIQ. They are cited here as the published mechanistic research behind this peptide class, not as evidence of an effect in any particular product or use case.

References

  1. Sikiric P, et al. The effect of pentadecapeptide BPC 157, H2-blockers, omeprazole and sucralfate on new vessels and new granulation tissue formation. J Physiol Paris. 1999;93(6):479-85. PMID: 10672992
  2. Japjec M, et al. Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats. Biomedicines. 2021. PMID: 34829776
  3. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019. PMID: 30915550
  4. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-8. PMID: 10469335
  5. Philp D, Goldstein AL, Kleinman HK. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004;125(2):113-5. PMID: 15037013
This article is for laboratory research reference only. All studies cited above are animal-model or in vitro research, not human clinical findings. All compounds discussed are intended strictly for research and laboratory use — not for human or animal consumption. Nothing here constitutes dosing, medical, or health guidance.
Compounds referenced in this article
Related research and lab guides
Browse ROVIQ Research Compounds →